Recombined protein carrier PEA II-HphA of actively carrying exogenic gene, its preparing method and use

Abstract

This invention openly carrying a foreign gene active recombinant protein carrier core area PEAII-HphA and preparation methods and application, but also take the initiative to open a foreign gene carrying the recombinant protein carrier core gene fragment PEAII-HphA ; The initiative delivery exogenous gene's reorganization protein carrier is by guidance member - PEA toxin cross membrane indexing area PEAII- ultra is addicted to the hot Archaea histone HphA composition protein; Under the guidance member's guidance, on the carrier and the target cell's acceptor specificity union has manifested its target tropism, lies between in the acceptor leads passes PEA IIThe cross membrane transportation enters in cell's to swallow the function traversing cell membrane on own initiative, has manifested its initiative, raised the gene transportation efficiency effectively . HphA combination of DNA, and a strong ability with the exogenous gene complexes formed in the active transport carrier in the process, arrived at the exogenous gene, increasing its expression efficiency, cell non-toxic, more secure; Superior to the traditional vector and liposomes,it can be widely used in gene therapy and transgenic animal research.

Description

technical field [0001] The present invention relates to a recombinant protein carrier for actively carrying exogenous genes, its preparation method and the use of medicines. Background technique [0002] Gene therapy is a new disease treatment model developed in the 1990s. Its definition is relatively broad. Broadly speaking, gene therapy is a method of applying genes or gene products to treat diseases. In a narrow sense, gene therapy is a treatment method that transfers normal genes or therapeutic genes from the outside world to target cells of the human body through vectors for gene modification and expression, and improves diseases. Gene therapy is a fundamental treatment. It can achieve the purpose of treatment by replacing mutated disease-causing genes, changing the genetic structure of diseased cells, or by introducing genes to enhance the body's immunity. Compared with traditional drug treatment, the above measures are fundamentally controlling the disease. In 1990...

AI Technical Summary

Problems solved by technology

Antisense drugs are easily degraded by endogenous nucleases, so their stability is not high, which is an important defect affecting their application

[0017] Non-viral gene therapy has been developed for more than ten years, and some achievements have been made, but there are still some problems: (1) How does the vector carry DNA into the cell? How does DNA enter the nucleus and play a role in the specific process? How the drug protein is expressed and how the gene is turned off is still not well understood

(2) The non-viral transfer system faces the problems of short expression time and low expression efficiency

(3) Although safety is a major advantage of non-viral gene therapy, its disadvantages such as non-targeting, short expression time, low expression efficiency, limited overall application, and the safety of long-term application need further investigation

Images